Loading stock…

Novavax, Inc. (NVAX) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

NVAXNovavax

Revenue FY25$1.1B

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-17%1

Revenue, next 1Y-66%1

Revenue, next 3Y, CAGR-35%1

Revenue, next 5Y, CAGR-17%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Revenue fell 17%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Revenue is set to shrink 35%/yr over the next 3 years, behind most of the market.1/10

Revenue fell 17%/yr over the last 3 years and is set to shrink 35%/yr from here.

Over five years revenue is set to shrink 17%/yr, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG71 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+12%10

3-month return+17%9

YTD return+64%10

MID & LONG-TERM▾SCORE

% of 52-week high82%6

1-year return+28%8

3-year return+53%6

5-year return-93%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 28% over the past year, but 18% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+12%), over three months (+17%) and so far this year (+64%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+53% over three years and -93% over five), behind 60% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Novavax, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

NVAXNovavax

Revenue FY25$1.1B

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-17%1

Revenue, next 1Y-66%1

Revenue, next 3Y, CAGR-35%1

Revenue, next 5Y, CAGR-17%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Revenue fell 17%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Revenue is set to shrink 35%/yr over the next 3 years, behind most of the market.1/10

Revenue fell 17%/yr over the last 3 years and is set to shrink 35%/yr from here.

Over five years revenue is set to shrink 17%/yr, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG71 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+12%10

3-month return+17%9

YTD return+64%10

MID & LONG-TERM▾SCORE

% of 52-week high82%6

1-year return+28%8

3-year return+53%6

5-year return-93%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 28% over the past year, but 18% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+12%), over three months (+17%) and so far this year (+64%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+53% over three years and -93% over five), behind 60% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Novavax, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Novavax, Inc.

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Novavax, Inc.. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Novavax, Inc.. Get the full investment case.

Premium